Novo Holdings leads $100 million Series C financing of Asceneuron to advance groundbreaking therapy for Alzheimer's disease

Funds will be used to progress lead asset ASN51, an oral small molecule OGA inhibitor, into Phase 2 clinical development for the treatment of Alzheimer's diseaseAlzheimer's disease is an area of very high unmet medical need with a lack of oral disease modifying therapiesNaveed Siddiqi, Senior Partner, Venture Investments, Novo Holdings will join Asceneuron Board of DirectorsView original content:https://www.prnewswire.co.uk/news-releases/novo-holdings-leads-100-million-series-c-financing-of-asceneuron-to-advance-groundbreaking-therapy-for-alzheimers-disease-302197021.html

en | boerse | 67936191 |